Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 12 29 3 14
Substance-Related Disorders 42 69
Substance Abuse Problem 69

Classifications:



External Ids:

Disease Ontology 12 DOID:302
MeSH 42 D019966
NCIt 47 C16522
SNOMED-CT 64 26416006
UMLS 69 C0013146

Summaries for Substance Abuse

Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to multiple personality disorder and antisocial personality disorder, and has symptoms including symptoms An important gene associated with Substance Abuse is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Peptide ligand-binding receptors and Beta-Adrenergic Signaling. The drugs Amphetamine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

CDC : 3 Data are for the U.S.

Wikipedia : 72 Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the... more...

Related Diseases for Substance Abuse

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
id Related Disease Score Top Affiliating Genes
1 multiple personality disorder 31.9 DRD4 MAOA
2 antisocial personality disorder 31.4 DRD2 DRD3 DRD4
3 personality disorder 29.4 BDNF COMT CYP2D6 DRD2 DRD3 DRD4
4 hepatitis d 28.3 BDNF COMT CYP2D6 DRD2 DRD4 MAOA
5 schizophrenia 25.7 BDNF COMT CYP2D6 DBH DRD2 DRD3
6 eating disorder 11.3
7 alcohol abuse 11.2
8 cocaine abuse 11.1
9 opioid abuse 11.1
10 cannabis abuse 11.1
11 panic disorder 10.8
12 antidepressant type abuse 10.8
13 hallucinogen abuse 10.8
14 phencyclidine abuse 10.8
15 amphetamine abuse 10.8
16 barbiturate abuse 10.8
17 impulse control disorder 10.8
18 placenta disease 10.7 DRD2 DRD3 DRD4
19 c8 deficiency, type ii 10.7 COMT DRD2 DRD4
20 intracranial cavernous angioma 10.7 DRD2 SLC6A3 SLC6A4
21 ulcerative colitis 10.7 BDNF COMT DRD2
22 dissociative disorder 10.6 DRD3 SLC6A4
23 anosognosia 10.6 COMT DRD2 SLC6A4
24 splenic abscess 10.6 DRD2 SLC6A3 SLC6A4
25 brain meningioma 10.6 BDNF COMT DRD2
26 rhinoscleroma 10.6 COMT DRD2 PRL
27 suppurative periapical periodontitis 10.6 DRD2 DRD3 SLC6A4
28 uterus intravascular leiomyomatosis 10.6 COMT MAOA SLC6A4
29 primary angle-closure glaucoma 10.6 BDNF COMT SLC6A4
30 ring chromosome 14 syndrome 10.6 COMT MAOA
31 asperger syndrome 10.6 DRD2 DRD3 SLC6A3
32 anodontia 10.5 HTR1B SLC6A3 SLC6A4
33 hypertrophy of breast 10.5 DRD4 PRL SLC6A3
34 conjunctival pigmentation 10.5 MAOA SLC6A4
35 ganglioneuroma 10.5 DRD2 DRD3 SLC6A3
36 eosinophilia-myalgia syndrome 10.5 BDNF DRD2 DRD4 SLC6A3
37 hallucinogen dependence 10.5 BDNF DRD2 DRD3 SLC6A4
38 hypoglycemic coma 10.5 BDNF MAOA SLC6A4
39 pelvic inflammatory disease 10.5 DBH DRD2 SLC6A4
40 simpson-golabi-behmel syndrome 10.5 DBH DRD2 SLC6A3
41 vallecula cancer 10.5 COMT MAOA SLC6A4
42 postencephalitic parkinson disease 10.5 BDNF DRD2 MAOA SLC6A4
43 intrahepatic gall duct cancer 10.4 BDNF COMT MAOA SLC6A4
44 water-clear cell adenoma 10.4 DRD2 PRL
45 ornithosis 10.4 DRD2 MAOA PRL SLC6A4
46 acquired aneurysmal subarachnoid hemorrhage 10.4 CYP2D6 MAOA SLC6A4
47 may-hegglin anomaly 10.4 COMT MAOA SLC6A4
48 parkinsonism-dystonia, infantile 10.4 COMT DRD2 MAOA SLC6A3
49 teebi kaurah syndrome 10.4 COMT CYP2D6 DRD2 DRD3
50 dyspepsia 10.4 NPY PRL

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 SLC6A3 SLC6A4 TDO2 BDNF COMT DBH
2 homeostasis/metabolism MP:0005376 10.03 PRL SLC6A3 SLC6A4 TDO2 TF BDNF
3 endocrine/exocrine gland MP:0005379 9.91 SLC6A4 BDNF COMT DBH DRD2 DRD5
4 integument MP:0010771 9.56 BDNF DBH DRD2 GABRA2 PRL SLC6A3
5 nervous system MP:0003631 9.53 BDNF COMT DBH DRD2 DRD3 DRD4

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 300-62-9 5826 3007
2
Aripiprazole Approved, Investigational Phase 4,Phase 2,Phase 1 129722-12-9 60795
3
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
4
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
5
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
6
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
7
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 249296-44-4 5310966
8
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
9
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1 54-11-5 942 89594
10
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
11
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 465-65-6 5284596
12
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
13
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
14
Disulfiram Approved Phase 4,Phase 1 97-77-8 3117
15
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
16
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 537-46-2 10836
17
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2,Early Phase 1 76-42-6 5284603
18
Valproic Acid Approved, Investigational Phase 4,Phase 3 99-66-1 3121
19
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
20
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
21
Sertraline Approved Phase 4,Phase 2 79617-96-2 68617
22
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 16590-41-3 5360515
23
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
24
Lorazepam Approved Phase 4,Phase 1,Phase 2 846-49-1 3958
25
Clozapine Approved Phase 4 5786-21-0 2818
26
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
27
Desipramine Approved Phase 4,Phase 2 50-47-5 2995
28
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
29
Dextroamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1 51-64-9 5826
30
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
31
Sofosbuvir Approved Phase 4,Phase 3 1190307-88-0 45375808
32
Ziprasidone Approved Phase 4 146939-27-7 60854
33
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
34
Choline Approved, Nutraceutical Phase 4 62-49-7 305
35
Betadex Experimental Phase 4 7585-39-9 320761
36 Antipsychotic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
37 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1
47 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Nicotinic Agonists Phase 4,Phase 3,Phase 2,Phase 1
50 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1022)

id Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
2 Cognitive Correlates of Substance Abuse, Part 2 - 16 Unknown status NCT00000351 Phase 4
3 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
4 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
5 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4 Varenicline;Placebo
6 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4 atomoxetine
7 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
8 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
9 Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
10 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
11 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
12 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
13 Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse Completed NCT00573534 Phase 4 Vyvanse
14 Facilitating the Adoption of Evidence-Based Depression Management in Substance Use Treatment Programs Completed NCT00137306 Phase 4
15 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
16 Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
17 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
18 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients Completed NCT00295412 Phase 4 quetiapine (drug)
19 The Whole Day First Grade Program Completed NCT00257088 Phase 4
20 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
21 Study of Aripiprazole in Subjects With Alcoholism Completed NCT00082199 Phase 4 Aripiprazole;Placebo
22 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
23 PROlonGed ExpoSure Sertraline Completed NCT01524133 Phase 4 Sertraline
24 Use of Naltrexone in a Clinical Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
25 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Completed NCT00156715 Phase 4 Quetiapine
26 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
27 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
28 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
29 Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
30 Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
31 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
32 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
33 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
34 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
35 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
36 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
37 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
38 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
39 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Drug;Placebo
40 Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Completed NCT01673594 Phase 4 SODAS MPH;Naltrexone
41 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
42 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
43 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
44 Substance Dependent Teens - Impact of Treating Depression Study 1 - 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
45 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4 Desipramine
46 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
47 Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users Completed NCT00194480 Phase 4 Pegylated Interferon
48 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
49 STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse Completed NCT00369746 Phase 4 citalopram
50 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

id Genetic test Affiliating Genes
1 Substance Abuse 29

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

39
Testes, Brain, Liver, Kidney, Pituitary, Lung, Spinal Cord

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 713)
id Title Authors Year
1
Differences in Psychoactive Substance Abuse Between Youths Residing in and Outside Conflict Zones as a Function of Level of Religiosity and Political Commitment. ( 28714800 )
2017
2
Family and Peer-Group Substance Abuse as a Risk-Factor for Opioid Misuse Behaviors for a Young Adult with Cancer-Related Pain-A Case Study. ( 28910174 )
2017
3
Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse. ( 28057187 )
2017
4
Recovery From Substance Abuse Among Zimbabwean Men: An Occupational Transition. ( 28685660 )
2017
5
Follow-up protocol was useful for children whose parents attended emergency departments after partner violence, substance abuse or a suicide attempt. ( 28929523 )
2017
6
Current status and future prospects for the development of substance abuse vaccines. ( 28918668 )
2017
7
Did you get any help? A post-hoc secondary analysis of a randomized controlled trial of psychoeducation for patients with antisocial personality disorder in outpatient substance abuse treatment programs. ( 28068951 )
2017
8
Gender differences in substance abuse, PTSD and intentional self-harm among veterans health administration patients. ( 28013099 )
2017
9
Tinnitus, Anxiety, Depression and Substance Abuse in Rock Musicians a Norwegian Survey. ( 28723602 )
2017
10
Predictors of Return Visits Among Insured Emergency Department Mental Health and Substance Abuse Patients, 2005-2013. ( 28874941 )
2017
11
Screening, Brief Intervention and Referral to Treatment: implications of SAMHSA's SBIRT initiative for substance abuse policy and practice. ( 28074569 )
2017
12
Are There Tools to Screen Children and Adolescents in the Emergency Department With Mental Health and Substance Abuse Issues? ( 28935284 )
2017
13
The relationship between ocular trauma and substance abuse in emergency department patients. ( 28705744 )
2017
14
Modeling spatio-temporal variations of substance abuse mortality in Iran using a log-Gaussian Cox point process. ( 28760264 )
2017
15
Social Support Influences on Substance Abuse Outcomes Among Sober Living House Residents with Low and Moderate Psychiatric Severity. ( 28757663 )
2017
16
Substance dependence among those without symptoms of substance abuse in the World Mental Health Survey. ( 28211594 )
2017
17
Decreased NOX2 expression in the brain of patients with bipolar disorder: association with valproic acid prescription and substance abuse. ( 28809856 )
2017
18
Mothers' experiences of coping with adolescent substance abuse: a phenomenological inquiry. ( 28760077 )
2017
19
Assessing the Mental Health, Substance Abuse, Cognitive Functioning, and Social/Emotional Well-Being Needs of Aboriginal Prisoners in Australia. ( 28823188 )
2017
20
Mental Health, Substance Abuse, and Suicide Among Homeless Adults. ( 28678621 )
2017
21
Childhood sexual abuse and substance abuse: A gender paradox? ( 27912908 )
2017
22
Offenders With Substance Abuse Who Receive Mandatory Psychiatric Treatment. ( 28939729 )
2017
23
A Post-Hurricane Katrina Examination of Substance Abuse Treatment Discharges with Co-Occurring Psychiatric and Substance Use Disorders. ( 28045601 )
2017
24
Childhood Maltreatment and Unprotected Sex among Female Juvenile Offenders: Evidence of Mediation by Substance Abuse and Psychological Distress. ( 28087129 )
2017
25
Socioeconomic differences in adolescent substance abuse treatment participation and long-term outcomes. ( 28088743 )
2017
26
Opioids and Substance Abuse: Education or Just Regulation? ( 28755098 )
2017
27
Co-Occurrence of and Recovery from Substance Abuse and Lifespan Victimization: A Qualitative Study of Female Residents in Trauma-Informed Sober Living Homes. ( 28085637 )
2017
28
Failure to get into substance abuse treatment. ( 28017185 )
2017
29
The impaired anesthesiologist: what you should know about substance abuse. ( 27928715 )
2017
30
Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential. ( 28072812 )
2017
31
Evaluation of the AC-OK mental health and substance abuse screening measure in an international sample of Latino immigrants. ( 28888151 )
2017
32
Interagency collaboration: Strengthening substance abuse resources in child welfare. ( 28064109 )
2017
33
Substance abuse in the anesthesia block room by a patient. ( 28915425 )
2017
34
Rescuing Israeli travellers: effects of substance abuse, mental health, geographic region of rescue, gender and age of rescuees. ( 28931135 )
2017
35
Probation Staff Attitudes Toward Substance Abuse Treatment and Evidence-Based Practices. ( 27220361 )
2016
36
Oxazepam for the Treatment of Substance Abuse and Depression: Is it Appropriate? ( 27135891 )
2016
37
Preventing Substance Abuse With Data-Driven Coalitions. ( 27180417 )
2016
38
Prevalence and risk factors of alcohol and substance abuse among motorcycle drivers in Fars province, Iran. ( 27140214 )
2016
39
Evaluating Measures of Fidelity for Substance Abuse Group Treatment With Incarcerated Adolescents. ( 27211991 )
2016
40
The behavioral economics of young adult substance abuse. ( 27151545 )
2016
41
Policy on Substance Abuse in Adolescent Patients. ( 27931426 )
2016
42
Epistatic interactions involving DRD2, DRD4, and COMT polymorphisms and risk of substance abuse in women with binge-purge eating disturbances. ( 26950642 )
2016
43
The National Acupuncture Detoxification Association protocol, auricular acupuncture to support patients with substance abuse and behavioral health disorders: current perspectives. ( 27994492 )
2016
44
Examination of Life Satisfaction, Child Maltreatment Potential and Substance Use in Mothers Referred for Treatment by Child Protective Services for Child Neglect and Substance Abuse: Implications for Intervention Planning. ( 27617042 )
2016
45
Hospital care for mental health and substance abuse conditions in Parkinson's disease. ( 27943472 )
2016
46
Social Functioning and Self-Esteem of Substance Abuse Patients. ( 27654242 )
2016
47
Interventions for Adolescent Substance Abuse: An Overview of Systematic Reviews. ( 27664597 )
2016
48
Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. ( 27601909 )
2016
49
Mental health care in post-genocide Rwanda: evaluation of a program specializing in posttraumatic stress disorder and substance abuse. ( 27610238 )
2016
50
Considering the Contemporary Issues and Unresolved Challenges Facing Therapeutic Communities for Clients with Alcohol and Substance Abuse. ( 27128141 )
2016

Variations for Substance Abuse

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 DRD2 DRD3 DRD4 DRD5 GABRA2 HTR1B
2
Show member pathways
12.64 BDNF DRD2 DRD3 DRD4 DRD5
3
Show member pathways
12.47 COMT DRD2 DRD3 DRD4 DRD5 MAOA
4 12.19 DRD2 DRD3 DRD4 DRD5
6
Show member pathways
12.07 BDNF DRD2 DRD5 HTR1B NPY
7 11.93 BDNF MAOA PLP1 SLC6A4 TF
8
Show member pathways
11.86 BDNF DRD2 MAOA SLC6A3
9 11.83 CYP2D6 HTR1B MAOA SLC6A4
10
Show member pathways
11.78 DRD2 DRD3 DRD4
11 11.69 DBH MAOA TDO2
12
Show member pathways
11.61 DRD2 DRD3 DRD4 DRD5 HTR1B
13
Show member pathways
11.58 COMT DBH MAOA
14 11.08 HTR1B MAOA SLC6A4
15 10.98 DRD2 DRD3 DRD5
16
Show member pathways
10.95 COMT DBH MAOA
17 10.72 COMT MAOA
18
Show member pathways
10.71 COMT MAOA
19
Show member pathways
10.69 COMT MAOA SLC6A3 SLC6A4
20
Show member pathways
10.65 DBH MAOA SLC6A3 SLC6A4 TDO2

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 DRD2 DRD3 DRD4 DRD5 HTR1B SLC6A3
2 integral component of membrane GO:0016021 9.8 COMT CYP2D6 DBH DRD2 DRD3 DRD4
3 axon GO:0030424 9.46 COMT DRD2 GABRA2 SLC6A3
4 endocytic vesicle GO:0030139 8.8 DRD2 DRD3 TF

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.97 DBH DRD5 HTR1B NPY PLP1
2 response to drug GO:0042493 9.95 COMT DRD2 DRD3 HTR1B SLC6A3 SLC6A4
3 response to ethanol GO:0045471 9.91 DRD2 DRD3 HTR1B SLC6A3
4 cellular calcium ion homeostasis GO:0006874 9.88 DRD3 DRD4 DRD5
5 locomotory behavior GO:0007626 9.86 DBH DRD2 DRD3 SLC6A3
6 learning GO:0007612 9.84 COMT DRD3 DRD5
7 social behavior GO:0035176 9.83 DRD3 DRD4 SLC6A4
8 visual learning GO:0008542 9.83 DBH DRD2 DRD3
9 neurotransmitter transport GO:0006836 9.82 GABRA2 SLC6A3 SLC6A4
10 feeding behavior GO:0007631 9.81 DRD2 HTR1B NPY
11 negative regulation of adenylate cyclase activity GO:0007194 9.81 DRD2 DRD3 DRD4
12 negative regulation of blood pressure GO:0045776 9.77 DRD2 DRD3 DRD5
13 associative learning GO:0008306 9.77 DBH DRD2 DRD5
14 arachidonic acid secretion GO:0050482 9.75 DRD2 DRD3 DRD4
15 regulation of dopamine secretion GO:0014059 9.72 DRD2 DRD3 HTR1B
16 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
17 response to pain GO:0048265 9.71 COMT DBH
18 vasoconstriction GO:0042310 9.71 HTR1B SLC6A4
19 negative regulation of cAMP biosynthetic process GO:0030818 9.71 DRD4 HTR1B
20 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.71 DRD2 HTR1B
21 behavioral response to cocaine GO:0048148 9.71 DRD2 DRD3 DRD4
22 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
23 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.7 DRD2 DRD5
24 negative regulation of voltage-gated calcium channel activity GO:1901386 9.7 DRD2 DRD4
25 synaptic transmission, dopaminergic GO:0001963 9.7 DRD2 DRD3 DRD5
26 ammonium transmembrane transport GO:0072488 9.69 SLC6A3 SLC6A4
27 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 DRD3
28 behavior GO:0007610 9.69 HTR1B NPY
29 negative regulation of protein secretion GO:0050709 9.69 DRD2 DRD3 DRD4
30 neurotransmitter catabolic process GO:0042135 9.68 COMT MAOA
31 catecholamine metabolic process GO:0006584 9.68 COMT MAOA
32 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 DRD3 DRD5
33 regulation of dopamine metabolic process GO:0042053 9.68 DRD4 SLC6A3
34 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
35 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
36 behavioral response to ethanol GO:0048149 9.67 DBH DRD2 DRD4
37 dopamine uptake involved in synaptic transmission GO:0051583 9.66 SLC6A3 SLC6A4
38 regulation of cAMP metabolic process GO:0030814 9.66 DRD2 DRD3
39 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.65 DRD2 DRD3
40 fear response GO:0042596 9.63 DBH DRD4
41 prepulse inhibition GO:0060134 9.63 DRD2 DRD3 SLC6A3
42 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.62 DRD2 DRD4
43 negative regulation of dopamine receptor signaling pathway GO:0060160 9.62 DRD2 DRD3
44 acid secretion GO:0046717 9.61 DRD2 DRD3
45 G-protein coupled receptor internalization GO:0002031 9.61 DRD2 DRD3 HTR1B
46 regulation of locomotion involved in locomotory behavior GO:0090325 9.58 DRD2 DRD3
47 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD3 DRD4
48 dopamine metabolic process GO:0042417 9.56 COMT DRD2 DRD3 DRD4
49 response to cocaine GO:0042220 9.55 DRD2 DRD3 DRD5 HTR1B SLC6A3
50 dopamine receptor signaling pathway GO:0007212 9.54 DRD2 DRD3 DRD4

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.93 DRD2 DRD3 DRD4 DRD5 HTR1B NPY
2 signal transducer activity GO:0004871 9.8 DRD2 DRD3 DRD4 DRD5 HTR1B
3 drug binding GO:0008144 9.63 CYP2D6 DRD2 DRD3 DRD4 HTR1B SLC6A3
4 neurotransmitter:sodium symporter activity GO:0005328 9.48 SLC6A3 SLC6A4
5 structural constituent of myelin sheath GO:0019911 9.43 MOBP PLP1
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3 DRD4
7 monoamine transmembrane transporter activity GO:0008504 9.37 SLC6A3 SLC6A4
8 dopamine:sodium symporter activity GO:0005330 9.32 SLC6A3 SLC6A4
9 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD3 DRD4 DRD5
10 dopamine binding GO:0035240 9.02 DRD2 DRD3 DRD4 DRD5 SLC6A3

Sources for Substance Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....